National Comprehensive Cancer Network

Interactive CME


Educational Events & Programs

CONFERENCE DATES > Friday, September 30 – Saturday, October 1, 2016REGISTER >

CONFERENCE LOCATION > New York Marriott Marquis • New York, New York

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

This year's congress will kick off with Registration, Exhibits, and Refreshments on Friday, September 30th at 4:30 PM followed by educational sessions starting at 6:00 PM. The congress will end at 5:00 PM on Saturday, October 1st.

CO-CHAIRS:

Description: Ranjana H. Advani, MD

Ranjana H. Advani, MD
Stanford Cancer Institute

 

 

 

Description: Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

 

 

 

AGENDA*

Friday, September 30, 2016

 

4:30 – 6:00 PM     
Registration, Exhibits, and Refreshments

6:00 – 6:15 PM     
Opening Remarks

Moderators:
Ranjana H. Advani, MD
Stanford Cancer Institute

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

6:15 – 6:40 PM     
Myeloproliferative Neoplasms and Myelofibrosis: Evolving Management
Ruben A. Mesa, MD
Mayo Clinic Cancer Center

6:45 – 7:10 PM     
Does Generic Imatinib Change the Treatment Approach in CML?
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

7:15 – 7:40 PM     
AML: Are We Finally Making Real Progress?
Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

7:45 – 8:35 PM     
Patient Case Studies and Panel Discussion
(Elderly AML, Slow Responding or Emerging Mutation CML, “Incidental” Identification of a JAK2 Mutant Clone)

Panelists:
Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Ruben A. Mesa, MD
Mayo Clinic Cancer Center

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

 

Saturday, October 1, 2016

 

6:30 AM  – 5:00 PM
Registration Desk Open

7:00 – 8:15 AM     
Exhibits and Breakfast

8:15 – 8:20 AM     
Opening Remarks

Moderators:
Ranjana H. Advani, MD
Stanford Cancer Institute

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

8:20 – 9:10 AM     
Patient Case Studies and Panel Discussion
(Nasal NK/T-cell, Adult T-cell Leukemia/Lymphoma (ATLL), Primary Cutaneous Gamma-delta T-cell Lymphoma)

Panelists:
Ranjana H. Advani, MD
Stanford Cancer Institute

Francine Foss, MD
Yale Cancer Center/Smilow Cancer Hospital

Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center

9:15 – 9:40 AM     
How I Treat Peripheral T-cell Lymphoma
Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center

9:45 – 10:10 AM   
Supportive Care in the Management of T-cell Lymphomas
Erin Kopp, ACNP-BC
City of Hope Comprehensive Cancer Center

10:10 – 10:25 AM 
Break and Exhibits

10:25 – 10:50 AM 
Diffuse Large B-cell Lymphoma: Is Cell of Origin Necessary for Treatment Selection?
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

10:55 – 11:20 AM 
Early-stage Classical Hodgkin Lymphoma (CHL): Can We Eliminate Radiation Therapy for Most Patients?
Ranjana H. Advani, MD
Stanford Cancer Institute

11:25 AM – 12:00 PM          
Shared Decision Making at Key Points in the Management of Hematologic Malignancies
Thomas W. LeBlanc, MD, MA
Duke Cancer Institute

12:00 – 1:15 PM   
Lunch and Exhibits

12:10 – 1:10 PM
*Lunch Symposium:
 The Future of Targeted Therapies for
 Acute Myeloid Leukemia (AML)
Jointly provided by NCCN and PRIME® Education, Inc.

Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Richard M. Stone, MD
Dana-Farber Cancer Institute

This session is open to all health care providers attending the NCCN Hematologic Malignancies Congress; pre-registration is not required. CME/CNE/CPE available. Seating is limited to 150 people on a first-come, first-seated basis.

*The lunch symposium is supported by educational grants from Agios Pharmaceuticals; Astellas; and Novartis Pharmaceuticals Corporation.

1:15 – 2:05 PM     
Patient Case Studies and Panel Discussion
(Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma with Renal Failure)

Panelists:
Carol Ann Huff, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center

George Somlo, MD
City of Hope Comprehensive Cancer Center

2:10 – 2:35 PM     
Multiple Myeloma: Diagnosis and Primary Treatment
George Somlo, MD
City of Hope Comprehensive Cancer Center

2:40 – 3:05 PM     
How to Integrate the New Drugs into the Management of Multiple Myeloma
Carol Ann Huff, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

3:10 – 3:35 PM     
Getting Patients through Therapy: Supportive Care in Multiple Myeloma
Kathleen Colson, RN, BSN, BS
Dana-Farber Cancer Institutes

3:35 – 3:50 PM     
Break and Exhibits

3:50 – 4:15 PM     
ALL: New Options for Relapsed Disease
Rebecca B. Klisovic, MD
The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute

4:20 – 5:00 PM     
Debate—Examining Controversies in the Front-line Management of CLL: Chemo-immunotherapy vs. Continuous TKI Therapy
Steven Coutre, MD
Stanford Cancer Institute

William G Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center

5:00 PM 
Closing Remarks

Moderators:
Ranjana H. Advani, MD
Stanford Cancer Institute

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

*This agenda is subject to change.
Last updated on September 26, 2016


INTENDED AUDIENCE

This congress is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

ACCREDITATION INFORMATION

This congress is designated for AMA PRA Category 1 Credit™ and is also certified for credit for nurses and pharmacists.

SUPPORTERS

This activity is supported by educational funding provided by Amgen. This activity is supported by an independent educational grants from AbbVie and Incyte. Support provided by Actelion Pharmaceuticals US, Inc. This activity is supported by educational grants from: Acerta Pharma - A member of the AstraZeneca Group; Ariad Pharmaceuticals, Inc.; Astellas; Celgene Corporation; Genentech; MEI Pharma; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.; Seattle Genetics, Inc.; and Takeda Oncology.

(As of September 26, 2016)

FEES

Registration fee discounts are available to NCCN Member Institution employees! 
As a benefit of membership, NCCN extends a registration fee discount to staff employed at NCCN Member Institutions. Complimentary registration is available for residents, fellows and junior faculty at NCCN Member Institutions. Learn more.


Earn up to 8 credits online!

The NCCN 10th Annual Congress: Hematologic Malignancies™ took place October 16 – 17, 2015 in San Francisco, California. Recorded Presentations from this meeting are now available at education.nccn.org/hem2015.

Learn more about the NCCN Evidence Blocks™:


Exhibitor Information

Organizations who are interested in exhibiting at NCCN programs are encouraged to contact Jennifer Tredwell, Senior Director, Marketing.


Future Hematologic Malignancies Congress Dates:

  • NCCN 12th Annual Congress: Hematologic Malignancies™
    Friday, October 6, 2017 – Saturday, October 7, 2017
    Hilton San Francisco Union Square • San Francisco, California

Please check back often for the most up-to-date information. Please contact 866.788.NCCN (6226) or send an e-mail if you have additional questions.